MCID: SZR001
MIFTS: 61

Sezary's Disease

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Sezary's Disease

MalaCards integrated aliases for Sezary's Disease:

Name: Sezary's Disease 11 14 16
Sezary Syndrome 11 19 42 58 28 53 5 43 71 33
Sézary Syndrome 19 42 75 33
Sezary's Lymphoma 19 42
Sezary Erythroderma 42
Sezary Lymphoma 58
Sezary Disease 11

Characteristics:


Inheritance:

Sezary Syndrome: Multigenic/multifactorial 58

Prevelance:

Sezary Syndrome: <1/1000000 (United States, Norway) 58

Age Of Onset:

Sezary Syndrome: Adult 58

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


Summaries for Sezary's Disease

MedlinePlus Genetics: 42 Sézary syndrome is an aggressive form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. In Sézary syndrome, the cancerous T cells, called Sézary cells, are present in the blood, skin, and lymph nodes. A characteristic of Sézary cells is an abnormally shaped nucleus, described as cerebriform.People with Sézary syndrome develop a red, severely itchy rash (erythroderma) that covers large portions of their body. Sézary cells are found in the rash. However, the skin cells themselves are not cancerous; the skin problems result when Sézary cells move from the blood into the skin. People with Sézary syndrome also have enlarged lymph nodes (lymphadenopathy). Other common signs and symptoms of this condition include hair loss (alopecia), skin swelling (edema), thickened skin on the palms of the hands and soles of the feet (palmoplantar keratoderma), abnormalities of the fingernails and toenails, and lower eyelids that turn outward (ectropion). Some people with Sézary syndrome are less able to control their body temperature than people without the condition.The cancerous T cells can spread to other organs in the body, including the lymph nodes, liver, spleen, and bone marrow. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer.Sézary syndrome most often occurs in adults over age 60 and usually progresses rapidly; historically, affected individuals survived an average of 2 to 4 years after development of the condition, although survival has improved with newer treatments.Although Sézary syndrome is sometimes referred to as a variant of another cutaneous T-cell lymphoma called mycosis fungoides, these two cancers are generally considered separate conditions.

MalaCards based summary: Sezary's Disease, also known as sezary syndrome, is related to primary cutaneous t-cell non-hodgkin lymphoma and lymphoma, hodgkin, classic, and has symptoms including pruritus An important gene associated with Sezary's Disease is BCL10 (BCL10 Immune Signaling Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Denileukin diftitox and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include t cells, skin and bone marrow, and related phenotypes are dry skin and neoplasm of the skin

GARD: 19 Sezary syndrome is an aggressive form of cutaneous T-cell lymphoma which is a group of disorders that occur when T-cells (a type of white blood cell) become cancerous and affect the skin. It is characterized by a widespread red rash that may cover most of the body, the presence of cancerous T cells (called Sezary cells) in the blood, and abnormally enlarged lymph nodes. Other signs and symptoms may include intense itchiness, scaling and peeling of the skin; fever; weight loss; hair loss; outward turning of the eyelids (ectropion); palmoplantar keratoderma; malformation of the nails; and hepatosplenomegaly. The exact cause of Sezary syndrome is currently unknown.

Orphanet: 58 Sézary syndrome (SS) is an aggressive form of cutaneous T-cell lymphoma characterized by a triad of erythroderma, lymphadenopathy and circulating atypical lymphocytes (Sézary cells).

Wikipedia: 75 Sézary disease, or Sézary syndrome, is a type of cutaneous T-cell lymphoma that was first described by... more...

Related Diseases for Sezary's Disease

Diseases related to Sezary's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 417)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous t-cell non-hodgkin lymphoma 31.7 MIR17 IL7 IL5 IL4 IL2RA IL2
2 lymphoma, hodgkin, classic 31.1 IL7 IL2RA IL2 CD28 CCR4
3 dermatitis 31.0 IL5 IL4 IL2 CTLA4 CCR4 CCR10
4 leukemia, chronic lymphocytic 31.0 MIR223 MIR17 IL7 IL4 IL2RA IL2
5 exanthem 31.0 IL4 IL2 IFNA1 CTLA4
6 skin disease 30.9 MIR342 MIR223 MIR17 IL7 IL5 IL4
7 adult t-cell leukemia/lymphoma 30.9 IL2RA IL2 CTLA4 CD7 CCR4
8 peripheral t-cell lymphoma 30.9 MIR17 IL2RA CD7 CCR4
9 peripheral nervous system disease 30.9 MIR342 MIR17 IL4 IL2 IFNA1 DPP4
10 leishmaniasis 30.8 IL5 IL4 IL2 CTLA4
11 severe combined immunodeficiency 30.8 IL7 IL5 IL4 IL2RA IL2 DPP4
12 t-cell acute lymphoblastic leukemia 30.8 MIR223 MIR17 IL5 IL2RA IL2 CD7
13 cutaneous leishmaniasis 30.7 IL5 IL4 IL2
14 chickenpox 30.7 IL4 IL2 IFNA1 CTLA4
15 diphtheria 30.7 IL5 IL4 IL2RA IL2 IFNA1
16 contact dermatitis 30.7 IL5 IL4 IL2 CCR4
17 dermatitis, atopic 30.7 IL5 IL4 IL2RA IL2 CTLA4 CCR4
18 alopecia areata 30.7 IL4 IL2RA IL2 CTLA4
19 psoriasis 30.7 TNFRSF1B MIR17 IL7 IL5 IL4 IL2RA
20 acute graft versus host disease 30.7 IL2RA IL2
21 hairy cell leukemia 30.7 IL2RA IL2 IFNA1
22 fungal infectious disease 30.7 IL5 IL4 IL2
23 viral infectious disease 30.6 IL7 IL4 IL2RA IL2 IFNA1 CTLA4
24 autoimmune disease 30.6 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
25 mature t-cell and nk-cell lymphoma 30.6 MIR17 IL2 CTLA4 CD7
26 uveitis 30.6 IL4 IL2RA IL2 CTLA4
27 lymphoma, non-hodgkin, familial 30.6 MIR342 MIR223 MIR17 IL7 IL2RA IL2
28 t-cell adult acute lymphocytic leukemia 30.6 IL2 CD7 CCR4
29 hemophagocytic lymphohistiocytosis 30.5 IL7 IL2RA IL2 CTLA4
30 lymphopenia 30.5 IL7 IL4 IL2RA IL2 CTLA4
31 progressive multifocal leukoencephalopathy 30.5 IL7 IL2 CTLA4
32 hypereosinophilic syndrome 30.5 IL5 IL4 IL2RA IL2 IFNA1
33 systemic scleroderma 30.5 STAT4 IL4 IL2 IFNA1
34 hematologic cancer 30.5 MIR342 MIR223 MIR17 IL7 IL2RA IL2
35 leukemia, acute lymphoblastic 30.5 MIR223 MIR17 IL7 IL2 CTLA4 CD7
36 erythema multiforme 30.5 IL5 IL4 IL2
37 visceral leishmaniasis 30.5 IL5 IL4 IL2RA IL2
38 sarcoidosis 1 30.5 TNFRSF1B IL2RA IL2 CD28
39 kidney cancer 30.5 MIR342 MIR17 IL2 IFNA1
40 myeloma, multiple 30.5 MIR342 MIR17 IL7 IL4 IL2 IFNA1
41 acquired immunodeficiency syndrome 30.5 TNFRSF1B IL2RA IL2 IFNA1
42 pemphigoid 30.5 IL5 IL4 IL2
43 mycosis fungoides 30.4 TNFRSF1B PLS3 IL7 IL5 IL4 IL2RA
44 acute promyelocytic leukemia 30.4 MIR342 MIR223 MIR17 IFNA1 CD7
45 leukemia, acute myeloid 30.3 MIR342 MIR223 MIR17 IL7 IL4 IL2
46 immune deficiency disease 30.3 STAT4 MIR342 MIR223 MIR17 IL7 IL4
47 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.5 IL4 IL2
48 inflammatory bowel disease 18 10.5 IL4 CTLA4 CD28
49 chromium allergic contact dermatitis 10.5 IL5 IL4 IL2
50 skin sarcoidosis 10.5 IL2 IFNA1 CTLA4

Graphical network of the top 20 diseases related to Sezary's Disease:



Diseases related to Sezary's Disease

Symptoms & Phenotypes for Sezary's Disease

Human phenotypes related to Sezary's Disease:

58 30 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dry skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000958
2 neoplasm of the skin 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008069
3 pruritus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000989
4 erythroderma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001019
5 lichenification 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100725
6 lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002716
7 abnormal lymphocyte morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004332
8 cutaneous t-cell lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0012192
9 splenomegaly 58 30 Frequent (33%) Frequent (79-30%)
HP:0001744
10 hepatomegaly 58 30 Frequent (33%) Frequent (79-30%)
HP:0002240
11 immunodeficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0002721
12 palmoplantar keratoderma 58 30 Frequent (33%) Frequent (79-30%)
HP:0000982
13 alopecia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001596
14 nail dystrophy 58 30 Frequent (33%) Frequent (79-30%)
HP:0008404
15 tremor 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001337
16 abnormal facial shape 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001999
17 skeletal muscle atrophy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003202
18 peripheral neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009830
19 ectropion 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000656
20 gangrene 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100758
21 irregular hyperpigmentation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0007400
22 edema 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000969
23 abnormal immunoglobulin level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010701
24 abnormal pleura morphology 30 Occasional (7.5%) HP:0002103
25 abnormality of the pleura 58 Occasional (29-5%)
26 lymphoma 58 Very frequent (99-80%)
27 abnormality of the face 58 Frequent (79-30%)

UMLS symptoms related to Sezary's Disease:


pruritus

GenomeRNAi Phenotypes related to Sezary's Disease according to GeneCards Suite gene sharing:

25 (show all 24)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.72 DPP4 IL4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.72 IFNA1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-109 9.72 DPP4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-14 9.72 IFNA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-145 9.72 IFNA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.72 CCR10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 IFNA1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-175 9.72 IFNA1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.72 CCR10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 IL4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.72 CCR10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-191 9.72 CCR10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-209 9.72 IFNA1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.72 IL4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.72 IL4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.72 IL4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.72 IFNA1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.72 IL4
19 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.72 IFNA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.72 IFNA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 IFNA1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.72 CCR10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-91 9.72 DPP4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-95 9.72 DPP4

MGI Mouse Phenotypes related to Sezary's Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.09 BCL10 CCR10 CCR4 CD28 CD7 CTLA4
2 endocrine/exocrine gland MP:0005379 10.03 BCL10 CCR10 CD28 CD7 CTLA4 DPP4
3 respiratory system MP:0005388 9.65 CCR4 CTLA4 DPP4 IFNA1 IL2 IL2RA
4 hematopoietic system MP:0005397 9.58 BCL10 CCR10 CCR4 CD28 CD7 CTLA4

Drugs & Therapeutics for Sezary's Disease

Drugs for Sezary's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denileukin diftitox Approved, Investigational Phase 4 173146-27-5
2
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 135413536
3
Crofelemer Approved Phase 4 33507-63-0, 148465-45-6 36511 44359816
4
Fosaprepitant Approved Phase 4 172673-20-0 219090 135413538
5 Neurotransmitter Agents Phase 4
6 Neurokinin-1 Receptor Antagonists Phase 4
7
Neurokinin A Phase 4 86933-74-6 55582
8 Antiemetics Phase 4
9 Gastrointestinal Agents Phase 4
10
Bexarotene Approved, Investigational Phase 3 153559-49-0 82146
11
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
12
Zanolimumab Investigational Phase 3 652153-01-0
13 Opiate Alkaloids Phase 3
14 Narcotic Antagonists Phase 3
15 Narcotics Phase 3
16
Brentuximab vedotin Approved, Investigational Phase 2 914088-09-8
17
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
18
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904
19
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
20
Ondansetron Approved, Withdrawn Phase 2 99614-02-5 4595
21
Melphalan Approved Phase 2 148-82-3 4053 460612
22
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
24
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
25
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
26
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
28
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
29
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
30
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
31
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
32
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
33
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030
34
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
35
Nivolumab Approved Phase 2 946414-94-4
36
Letermovir Approved, Investigational Phase 2 917389-32-3 9916099 45138674
37
Acetic acid Approved Phase 2 64-19-7 176
38
Mebendazole Approved, Vet_approved Phase 2 31431-39-7 4030
39
Piperazine Approved, Vet_approved Phase 2 110-85-0 4837
40
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
41
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
42
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
46
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
47
Busulfan Approved, Investigational Phase 2 55-98-1 2478
48
Rituximab Approved Phase 1, Phase 2 174722-31-7
49
Lenalidomide Approved Phase 2 191732-72-6 216326
50
Aldesleukin Approved Phase 1, Phase 2 110942-02-4

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
2 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
3 Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome Terminated NCT01625455 Phase 4 Aprepitant;Placebo
4 Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy Terminated NCT00127881 Phase 3 HuMax-CD4 (zanolimumab)
5 A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma Terminated NCT02811783 Phase 3 Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
6 PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME Unknown status NCT00002557 Phase 2 CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
7 Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome Unknown status NCT00157274 Phase 2 alemtuzumab
8 A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT) Unknown status NCT02542124 Phase 2
9 A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome Completed NCT02243579 Phase 2
10 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
11 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
12 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
13 A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL) Completed NCT00005080 Phase 2 nelarabine
14 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
15 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
16 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
17 A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma Completed NCT00961220 Phase 1, Phase 2 Carmustine;O6-Benzylguanine
18 A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H Completed NCT00047060 Phase 1, Phase 2 cyclosporine;fludarabine;Campath
19 Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome Completed NCT00057967 Phase 2
20 Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Sezary Syndrome Using Autologous Mature Dendritic Cells Completed NCT00099593 Phase 2
21 Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome Completed NCT00002479 Phase 2 tretinoin
22 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
23 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
24 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
25 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
26 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
27 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
28 Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma Completed NCT00178841 Phase 2 Rosiglitazone and Bexarotene
29 Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma Completed NCT00091559 Phase 2 MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
30 A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma Completed NCT00918333 Phase 1, Phase 2 panobinostat;everolimus
31 A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma Completed NCT00611208 Phase 2
32 A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy Completed NCT01075321 Phase 1, Phase 2 everolimus;lenalidomide
33 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
35 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
36 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
37 A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed NCT01261247 Phase 2 panobinostat
38 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
39 Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level Completed NCT01396070 Phase 2 Brentuximab vedotin
40 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
41 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
42 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
43 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
44 Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma Completed NCT00466921 Phase 2 lenalidomide
45 A Phase II, Open-Label, Single-Arm Trial Using KEYTRUDA (Pembrolizumab) as Initial Systemic Therapy in the Treatment of Advanced Mycosis Fungoides Recruiting NCT03695471 Phase 2
46 A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma Recruiting NCT04541017 Phase 1, Phase 2
47 A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL Recruiting NCT04930653 Phase 2
48 Pembrolizumab in Combination With Gemcitabine for Previously Treated Mycosis Fungoides and Sézary Syndrome: Efficacy and Characterization of Immune Response Recruiting NCT04960618 Phase 2 Gemcitabine;Pembrolizumab
49 Optimizing Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis Recruiting NCT03587844 Phase 2 brentuximab vedotin
50 TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma Recruiting NCT03902184 Phase 2

Search NIH Clinical Center for Sezary's Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: sezary syndrome

Genetic Tests for Sezary's Disease

Genetic tests related to Sezary's Disease:

# Genetic test Affiliating Genes
1 Sezary Syndrome 28

Anatomical Context for Sezary's Disease

Organs/tissues related to Sezary's Disease:

MalaCards : T Cells, Skin, Bone Marrow, Liver, Spleen, Bone, Skeletal Muscle

Publications for Sezary's Disease

Articles related to Sezary's Disease:

(show top 50) (show all 2189)
# Title Authors PMID Year
1
MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. 62 46
20448109 2010
2
Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. 5
9989495 1999
3
Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. 53 62
19239991 2008
4
Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma. 53 62
18569641 2008
5
Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. 53 62
17975162 2007
6
Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. 53 62
17546636 2007
7
Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. 53 62
16741518 2006
8
Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. 53 62
16197392 2005
9
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. 53 62
16172331 2005
10
CCR10 is expressed in cutaneous T-cell lymphoma. 53 62
15700309 2005
11
Biological effects of bexarotene in cutaneous T-cell lymphoma. 53 62
15781672 2005
12
Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. 53 62
15727636 2005
13
Aberrant expression of T-plastin in Sezary cells. 53 62
14612505 2003
14
Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. 53 62
12393503 2003
15
Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. 53 62
12393570 2003
16
Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. 53 62
12209749 2002
17
Diminished expression of the type II receptor for TGFbeta (TGFbetaRII) in T lymphocytes from patients with Sezary syndrome is not due to mutations in the receptor's poly-A tract: limitations of the standard RT-PCR in cDNA sequence analysis of homopolymeric base stretches. 53 62
12546068 2002
18
Association between Sézary T cell-activating factor, Chlamydia pneumoniae, and cutaneous T cell lymphoma. 53 62
11594584 2001
19
Photoactivational cytokine-modulatory action of 8-methoxypsoralen plus ultraviolet A in lymphocytes, monocytes, and cutaneous T cell lymphoma cells. 53 62
11594572 2001
20
Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. 53 62
11464181 2001
21
Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome. 53 62
11442758 2001
22
Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. 53 62
11453809 2001
23
Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. 53 62
11392886 2001
24
The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulation. 53 62
11407974 2001
25
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. 53 62
11368440 2001
26
Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). 53 62
11359391 2001
27
CD4(+)CD7(-) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sézary syndrome. 53 62
11209115 2001
28
Chromosomally clonal T cells in the skin, blood, or lymph nodes of two Sezary syndrome patients express CD45RA, CD45RO, CDw150, and interleukin-4, but no interleukin-2 or interferon-gamma. 53 62
11168816 2001
29
Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12. 53 62
11148473 2001
30
Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. 53 62
10491012 1999
31
Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sézary syndrome. 53 62
10354086 1999
32
Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. 53 62
10233261 1999
33
Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. 53 62
9639524 1998
34
Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity. 53 62
9649208 1998
35
Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. 53 62
9548535 1998
36
Sézary syndrome, T-helper 2 cytokines and accessory factor-1 (AF-1). 53 62
9613981 1998
37
Hypertriglyceridemia during long-term interferon-alpha therapy in a series of hematologic patients. 53 62
9181461 1997
38
Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sézary syndrome. 53 62
9129044 1997
39
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 53 62
8799169 1996
40
Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-gamma receptor beta-chain). 53 62
8695857 1996
41
The clonal nature of circulating Sezary cells. 53 62
7492785 1995
42
Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. 53 62
7963654 1994
43
Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. 53 62
7931473 1994
44
Keratinocyte interleukin-10 expression is upregulated in tape-stripped skin, poison ivy dermatitis, and Sezary syndrome, but not in psoriatic plaques. 53 62
7923918 1994
45
Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. 53 62
8080984 1994
46
Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome. 53 62
8113839 1994
47
Sézary T-cell-activating factor induces functional interleukin 2 receptors on T-cells derived from patients with Sézary syndrome. 53 62
8221690 1993
48
A CD2+ subset of non-malignant peripheral blood lymphocytes from patients with Sézary syndromes overexpress the low-molecular-weight GTP-binding protein Rab2. 53 62
8096558 1993
49
Soluble interleukin-2 receptor in Sézary syndrome: its origin and clinical application. 53 62
8457444 1993
50
Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. 53 62
1453206 1992

Variations for Sezary's Disease

ClinVar genetic disease variations for Sezary's Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BCL10 NM_003921.5(BCL10):c.428del (p.Phe143fs) DEL Pathogenic
6260 rs587776632 GRCh37: 1:85733584-85733584
GRCh38: 1:85267901-85267901

Copy number variations for Sezary's Disease from CNVD:

6 (show top 50) (show all 353)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 38537 10 103280000 105830000 Deletion ACTR1A Sezary syndrome
2 38538 10 103280000 105830000 Deletion ARL3 Sezary syndrome
3 38539 10 103280000 105830000 Deletion BTRC Sezary syndrome
4 38540 10 103280000 105830000 Deletion COL17A1 Sezary syndrome
5 38541 10 103280000 105830000 Deletion CYP17A1 Sezary syndrome
6 38542 10 103280000 105830000 Deletion FGF8 Sezary syndrome
7 38543 10 103280000 105830000 Deletion LDB1 Sezary syndrome
8 38544 10 103280000 105830000 Deletion OGA Sezary syndrome
9 38545 10 103280000 105830000 Deletion NEURL1 Sezary syndrome
10 38546 10 103280000 105830000 Deletion NFKB2 Sezary syndrome
11 38547 10 103280000 105830000 Deletion NT5C2 Sezary syndrome
12 38548 10 103280000 105830000 Deletion PCGF6 Sezary syndrome
13 38549 10 103280000 105830000 Deletion PDCD11 Sezary syndrome
14 38550 10 103280000 105830000 Deletion POLL Sezary syndrome
15 38551 10 103280000 105830000 Deletion PSD Sezary syndrome
16 38552 10 103280000 105830000 Deletion SH3PXD2A Sezary syndrome
17 38553 10 103280000 105830000 Deletion SLK Sezary syndrome
18 38554 10 103280000 105830000 Deletion SUFU Sezary syndrome
19 38555 10 103280000 105830000 Deletion TLX1 Sezary syndrome
20 38556 10 103280000 105830000 Deletion TRIM8 Sezary syndrome
21 39119 10 110240000 112960000 Deletion ADD3 Sezary syndrome
22 39120 10 110240000 112960000 Deletion DUSP5 Sezary syndrome
23 39121 10 110240000 112960000 Deletion MXI1 Sezary syndrome
24 39122 10 110240000 112960000 Deletion PDCD4 Sezary syndrome
25 39123 10 110240000 112960000 Deletion SMC3 Sezary syndrome
26 39709 10 118690000 123210000 Deletion BAG3 Sezary syndrome
27 39710 10 118690000 123210000 Deletion WDR11 Sezary syndrome
28 39711 10 118690000 123210000 Deletion CASC2 Sezary syndrome
29 39712 10 118690000 123210000 Deletion EIF3A Sezary syndrome
30 39713 10 118690000 123210000 Deletion EMX2 Sezary syndrome
31 39714 10 118690000 123210000 Deletion FGFR2 Sezary syndrome
32 39715 10 118690000 123210000 Deletion GFRA1 Sezary syndrome
33 39716 10 118690000 123210000 Deletion HSPA12A Sezary syndrome
34 39717 10 118690000 123210000 Deletion INPP5F Sezary syndrome
35 39718 10 118690000 123210000 Deletion NANOS1 Sezary syndrome
36 39719 10 118690000 123210000 Deletion PRDX3 Sezary syndrome
37 39720 10 118690000 123210000 Deletion PRLHR Sezary syndrome
38 39721 10 118690000 123210000 Deletion RGS10 Sezary syndrome
39 39722 10 118690000 123210000 Deletion TIAL1 Sezary syndrome
40 40284 10 126610000 131820000 Deletion ADAM12 Sezary syndrome
41 40285 10 126610000 131820000 Deletion BCCIP Sezary syndrome
42 40286 10 126610000 131820000 Deletion CTBP2 Sezary syndrome
43 40287 10 126610000 131820000 Deletion DHX32 Sezary syndrome
44 40288 10 126610000 131820000 Deletion DOCK1 Sezary syndrome
45 40289 10 126610000 131820000 Deletion MGMT Sezary syndrome
46 40290 10 126610000 131820000 Deletion MKI67 Sezary syndrome
47 40291 10 126610000 131820000 Deletion MMP21 Sezary syndrome
48 40292 10 126610000 131820000 Deletion PTPRE Sezary syndrome
49 40293 10 126610000 131820000 Deletion ZRANB1 Sezary syndrome
50 42175 10 29840000 33170000 Deletion ARHGAP12 Sezary syndrome

Expression for Sezary's Disease

Search GEO for disease gene expression data for Sezary's Disease.

Pathways for Sezary's Disease

Pathways related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 BCL10 CD28 CTLA4 IFNA1 IL2 IL2RA
2
Show member pathways
13.79 CCR10 CCR4 CD28 IL2 IL2RA IL4
3
Show member pathways
13.57 TNFRSF1B IL7 IL5 IL4 IL2RA IL2
4
Show member pathways
13.5 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
5
Show member pathways
13.36 TNFRSF1B STAT4 IL7 IL5 IL4 IL2RA
6
Show member pathways
13.27 IFNA1 IL2 IL2RA IL4 IL5 IL7
7
Show member pathways
13.24 CCR10 CCR4 CD28 IL2 IL2RA IL4
8
Show member pathways
12.93 RAB2A IL7 IL4 IL2RA IL2 IFNA1
9
Show member pathways
12.82 TNFRSF1B IL7 IL4 IL2RA IL2
10
Show member pathways
12.8 STAT4 IL2RA IL2 IFNA1 CD28
11
Show member pathways
12.62 STAT4 IL5 IL4 IL2RA IL2 IFNA1
12
Show member pathways
12.25 STAT4 IL5 IL2RA IL2
13
Show member pathways
12.23 IL2RA IL2 CTLA4 CD28 BCL10
14
Show member pathways
12.15 STAT4 IL2RA IL2 CD28
15 12.12 TNFRSF1B STAT4 IL4 IL2RA IL2 IFNA1
16
Show member pathways
11.98 BCL10 CD28 CTLA4 IL2 IL4 IL5
17
Show member pathways
11.96 STAT4 IL4 IL2RA IL2
18 11.95 IL7 IL5 IL4 IL2RA IL2 CD28
19
Show member pathways
11.86 STAT4 IL2 CD28
20
Show member pathways
11.82 STAT4 IL4 CD28
21 11.81 IL5 IL4 IL2RA IL2 CTLA4 CD28
22 11.73 IL2 IL4 IL5
23 11.7 IL7 IL5 IL4 IL2RA IL2 CD7
24 11.68 IL4 IL2RA IL2
25 11.68 IL5 IL4 IL2
26
Show member pathways
11.68 CTLA4 IL2 IL2RA IL4 IL5
27
Show member pathways
11.62 STAT4 IL5 IL4 IL2
28 11.51 TNFRSF1B IL4 IL2RA IL2 CD28 BCL10
29 11.5 IL4 IL2RA CTLA4
30
Show member pathways
11.37 TNFRSF1B IL2RA IL2
31 11.31 IL7 IL5 IL4
32 11.3 STAT4 IL5 IL4 IL2RA IL2 CD28
33 11.26 IL7 IL5 IL4 IL2
34 11.21 IL5 IL4 IL2
35 11.21 STAT4 IL2RA IL2 CD28
36 11.19 IL2 CTLA4 CD28
37 11.18 IL5 IL4 IL2
38 11.01 STAT4 IL2RA CTLA4
39 10.87 IL4 IL2
40 10.87 CTLA4 CD28
41 10.76 IL5 IL4
42 10.71 IL2RA IL2 CTLA4
43 10.67 IL2RA IL2
44 10.62 TNFRSF1B IL5 IL4 IL2RA IL2 CD28

GO Terms for Sezary's Disease

Cellular components related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex involved in cell adhesion GO:0098636 8.92 CTLA4 CD28

Biological processes related to Sezary's Disease according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 10.14 STAT4 IL7 IL5 IFNA1
2 cellular response to lipopolysaccharide GO:0071222 10.06 TNFRSF1B MIR342 MIR223 MIR17 BCL10
3 T cell activation GO:0042110 9.97 CD28 CD7 DPP4 IL4
4 negative regulation of inflammatory response GO:0050728 9.92 TNFRSF1B MIR223 IL4 IL2RA IL2
5 positive regulation of T cell proliferation GO:0042102 9.91 IL4 IL2RA IL2 CD28
6 activated T cell proliferation GO:0050798 9.87 IL2RA IL2
7 negative regulation of neuroinflammatory response GO:0150079 9.86 TNFRSF1B IL4
8 positive regulation of B cell proliferation GO:0030890 9.86 IL7 IL5 IL4 IL2
9 regulation of T cell homeostatic proliferation GO:0046013 9.8 IL2 IL2RA
10 regulation of CD4-positive, alpha-beta T cell proliferation GO:2000561 9.78 IL2RA IL2
11 regulation of T cell proliferation GO:0042129 9.71 TNFRSF1B CTLA4 CD28
12 negative regulation of lymphocyte proliferation GO:0050672 9.7 IL2RA IL2
13 negative regulation of neutrophil chemotaxis GO:0090024 9.69 MIR223 DPP4
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IL4 IL2 CD28
15 immune response GO:0006955 9.62 TNFRSF1B IL7 IL5 IL4 IL2RA IL2
16 lymphocyte proliferation GO:0046651 9.55 IL2RA IL2
17 positive regulation of T cell differentiation GO:0045582 9.5 IL2 IL2RA IL4 IL7

Molecular functions related to Sezary's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.86 IL7 IL5 IL4 IL2
2 cytokine activity GO:0005125 9.65 IL7 IL5 IL4 IL2 IFNA1
3 kinase activator activity GO:0019209 9.46 IL2 BCL10
4 cytokine receptor binding GO:0005126 8.8 IL7 IL4 IFNA1

Sources for Sezary's Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....